Nurse Webinar 4

Nurse webinar  4 will provide an overview of some of the common treatments for lymphoma/CLL. We will describe how the landscape is evolving with the introduction of new therapies over recent years.

The webinar will also explore the nursing implications of how new therapies for lymphoma & CLL have changed patient care.

Part 1: The evolving treatment landscape for lymphoma/CLL

Presented by Dr Katharine Lewis, Lymphoma Clinical/Research Fellow, Sir Charles Gairdner Hospital, Perth

Katharine is a Haematology Clinical/Research Fellow from the UK, who is working at Sir Charles Gairdner Hospital and Linear from August 2018. She graduated from the University of Nottingham in the UK in 2007 and has since completed most of her post graduate training in Nottingham, which is a large, tertiary referral centre for both malignant and non-malignant haematology, including stem cell transplantation.

Her particular field of interest is lymphoma, and she is working as a Lymphoma Clinical/Research Fellow.

Part 2: Patient care in the era of new therapies for lymphoma/CLL

Presented by Helena Furdas, Lymphoma Clinical Nurse Consultant, Sir Charles Gairdner Hospital, Perth.

Helena graduated from nursing at Curtin University in 2009 and shortly thereafter began her haematology experience in 2010 whilst working at Royal Perth Hospital on the Bone Marrow Transplant Unit. Since then she has continued to work in haematology and in 2015 transitioned with the State Centre for Allogeneic stem cell transplant to Fiona Stanley Hospital. Here she enjoyed working in the Cancer Centre providing care for patients to keep them well, happy and out of hospital. She was appointed by Sir Charles Gairdner Hospital as the Lymphoma Clinical Nurse Consultant in early 2020

Support and information

Share This

Contact Lymphoma Australia Today!

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.